Adult Somatic cells, such as skin cells, from patients can be used to derive induced pluripotent stem cells (iPS) by transduction of four Yamanaka transcription factors. Those patient specific iPS cells, with similar properties to embryonic stem (ES) cells, show great potential on various applications, such as drug screening and disease modeling. However, in applying this technique to therapeutic applications such as tissues regeneration, progress is often hampered by low efficiency (about 0.01 to 0.1%) and slow reprogramming (few weeks). Here, we present a novel way to overcome this...